Literature DB >> 12975755

Invasive aspergillosis in the setting of cardiac transplantation.

J G Montoya1, S V Chaparro, D Celis, J A Cortés, A N Leung, R C Robbins, D A Stevens.   

Abstract

Among patients undergoing heart transplantation, Aspergillus is the opportunistic pathogen with the highest attributable mortality. The median time of onset from transplantation for invasive pulmonary aspergillosis (IPA) was 46 days, but the median time to first positive culture result was 104 days among patients with Aspergillus colonization but no invasive disease. Most patients with IPA presented with fever and cough within the first 90 days of transplantation and with single or multiple pulmonary nodules. None of the heart transplant recipients with either IPA or invasive extrapulmonary aspergillosis (IEPA) had associated neutropenia. Human leukocyte antigen A1 locus was found significantly more frequently among patients colonized with Aspergillus than among patients with IPA (P<.006) or IEPA (P<.001). Even in the absence of neutropenia, IPA should be suspected for heart transplant recipients who have fever and respiratory symptoms within the first 3 months of transplantation, have a positive result of culture of respiratory secretions, and have abnormal radiological findings (particularly nodules).

Entities:  

Mesh:

Year:  2003        PMID: 12975755     DOI: 10.1086/376527

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  14 in total

Review 1.  Aspergillus infections in transplant recipients.

Authors:  Nina Singh; David L Paterson
Journal:  Clin Microbiol Rev       Date:  2005-01       Impact factor: 26.132

Review 2.  [Infections after organ transplantation].

Authors:  W V Kern; D Wagner; H H Hirsch
Journal:  Internist (Berl)       Date:  2005-06       Impact factor: 0.743

Review 3.  Cavitary pulmonary disease.

Authors:  L Beth Gadkowski; Jason E Stout
Journal:  Clin Microbiol Rev       Date:  2008-04       Impact factor: 26.132

4.  Aspergilloma of the heart.

Authors:  Suman Omana Soman; G Vijayaraghavan; N P Padmaja; Anoop R Warrier; Madhavan Unni
Journal:  Indian Heart J       Date:  2014-01-01

5.  Risk factors for invasive fungal disease in heart transplant recipients.

Authors:  Alexander S Rabin; Michael M Givertz; Gregory S Couper; Margaret M Shea; Driele Peixoto; Deborah S Yokoe; Lindsey R Baden; Francisco M Marty; Sophia Koo
Journal:  J Heart Lung Transplant       Date:  2014-10-02       Impact factor: 10.247

6.  Case of Renal Aspergillosis after Heart Transplant: Diagnosis and Treatment.

Authors:  M Mahdavi; G Mortaz-Hejri; H Shahzadi; H R Pouraliakbar; A Amin; M Hesami; B Naghavi
Journal:  Int J Organ Transplant Med       Date:  2021

Review 7.  Inhaled therapeutics for prevention and treatment of pneumonia.

Authors:  Amar Safdar; Samuel A Shelburne; Scott E Evans; Burton F Dickey
Journal:  Expert Opin Drug Saf       Date:  2009-07       Impact factor: 4.250

Review 8.  Lessons about the pathogenesis and management of aspergillosis from studies in chronic granulomatous disease.

Authors:  John I Gallin; Kol Zarember
Journal:  Trans Am Clin Climatol Assoc       Date:  2007

9.  Invasive aspergillosis among heart transplant recipients is rare but causes rapid death due to septic shock and multiple organ dysfunction syndrome.

Authors:  Ryan K Shields; M Hong Nguyen; Michael A Shullo; Fernanda P Silveira; Eun J Kwak; Rima C Abdel Massih; Yoshiya Toyoda; Christian A Bermudez; Jay K Bhama; Robert L Kormos; Cornelius J Clancy
Journal:  Scand J Infect Dis       Date:  2012-07-25

10.  Epidemiology and Outcomes of Hospitalizations With Invasive Aspergillosis in the United States, 2009-2013.

Authors:  Marya D Zilberberg; Brian H Nathanson; Rachel Harrington; James R Spalding; Andrew F Shorr
Journal:  Clin Infect Dis       Date:  2018-08-16       Impact factor: 9.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.